Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM)
A Phase 1 Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM)
Sponsor: EpicentRx, Inc.
This PHASE1 trial investigates Brain Metastases and is currently completed. EpicentRx, Inc. leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 7 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Dec 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
-
Jul 2018 — Dec 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- EpicentRx, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .